AOD-9604 vs MGF (Mechano Growth Factor)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

AOD-9604MGF (Mechano Growth Factor)
CategoryGrowth FactorsGrowth Factors
Standard DoseResearch indicates 250-300 mcg daily via subcutaneous injection, administered in the morning on an empty stomach.Research indicates 100-200 mcg per injection site, administered bilaterally into target muscles immediately post-workout.
TimingMorning administration on empty stomach, at least 30 minutes before eating. Fasted state enhances lipolytic effect.Immediately post-workout (within 5-10 minutes) for optimal satellite cell activation. Must be injected directly into the trained muscle.
Cycle Duration12-20 week cycles.4-6 week cycles.
Evidence Levelmoderate_humananimal_plus_anecdotal
A

AOD-9604

Growth Factors

Mechanism

AOD-9604 is a synthetic 16-amino acid fragment (residues 176-191) of the C-terminal domain of human growth hormone with a tyrosine substitution at the N-terminus. It selectively stimulates lipolysis by upregulating beta-3 adrenergic receptors in adipose tissue while inhibiting lipogenesis. It modulates lipid and glucose metabolism through beta-adrenergic and AMPK-related pathways without influencing IGF-1 activity, growth, or insulin sensitivity — retaining GH's fat-burning properties without its growth-promoting effects.

Standard Dosing

Research indicates 250-300 mcg daily via subcutaneous injection, administered in the morning on an empty stomach.

Timing

Morning administration on empty stomach, at least 30 minutes before eating. Fasted state enhances lipolytic effect.

Cycle Duration

12-20 week cycles.

Side Effects

  • Injection site reactions
  • Headache
  • Mild nausea
  • Transient hypoglycemia (rare)

Contraindications

  • Active cancer
  • Pregnancy and breastfeeding
  • Type 1 diabetes (use with caution)
  • Limited human evidence and sourcing variability

Best Stacking Partners

5-Amino-1MQMOTS-cCJC-1295/IpamorelinTesofensine

Mechanism

MGF is the E domain peptide of the IGF-1Ec splice variant, produced when the IGF-1 gene is mechanically spliced in response to muscle damage or exercise. It activates satellite cells (muscle stem cells), promoting their proliferation and preventing premature differentiation. After exercise/injury, IGF-1 gene is first spliced toward MGF (proliferation phase) then shifts to IGF-1Ea (differentiation phase). MGF uniquely drives the initial proliferative response, expanding the pool of myogenic precursor cells before they fuse with existing muscle fibers.

Standard Dosing

Research indicates 100-200 mcg per injection site, administered bilaterally into target muscles immediately post-workout.

Timing

Immediately post-workout (within 5-10 minutes) for optimal satellite cell activation. Must be injected directly into the trained muscle.

Cycle Duration

4-6 week cycles.

Side Effects

  • Injection site pain/swelling
  • Hypoglycemia (less than IGF-1 LR3)
  • Localized inflammation

Contraindications

  • Active cancer
  • Pregnancy and breastfeeding
  • Under 25 years of age

Best Stacking Partners

PEG-MGFIGF-1 LR3HGH

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →